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increasingly being used for both diagnostic coronary angiography
and percutaneous coronary intervention. Radial artery occlusion
is a complication of transradial catheterization that can lead to
permanent occlusion of the radial artery. Estimated incidence in
different studies is around 10%. Once radial artery is occluded, it
cannot be used for future catheterization and become inappro-
priate for bypass graft. Hand ischaemia due to radial artery oc-
clusion requiring medical or surgical attention is reported in 0.2%
of patients. So in our study we tried to assess incidence of radial
artery occlusion following transradial catheterization & also tried
to assess effect of placebo vs postprocedural intra arterial nitro-
glycerine on incidence of radial artery occlusion on day 1.
Methods: In our study we selected 430 patients who underwent
transradial catheterization. 226 patients were given post-
procedural 200ug nitroglycerine before removal of radial sheath
while 204 patient were given placebo. Next day all patients were
evaluated with duplex ultrasound for radial artery antegrade flow.
Results: Out of 430 patients, 144 had no antegrade flow in radial
artery. Incidence of radial artery occlusion on day 1was 33% in our
study.
Out of 226 patients who were given intra arterial nitroglycerine,
45 had no antegrade flow in radial artery.
While in placebo group out of 204 patients, 99 developed radial
artery occlusion. So, radial artery patency rate was significantly
higher (p value <0.001) in nitroglycerine group as compared to
placebo group.
Conclusion: Radial artery occlusion is usually a clinically silent
event due to good collateral from ulnar artery but Radial artery
occlusion cannot be ignored as it is having several disadvantages
for patient, cardiologist as well as for surgeon. Radial artery oc-
clusion rate can be minimized by this very simple intervention in
form of post procedural 200ug nitroglycerine before removal of
radial sheath.
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Background: Role of drug eluting balloons for in-stent re-stenosis
(ISR) and small vessel coronary artery disease was shown to be
promising. DEB alone was shown to be superior to drug eluting
stent in ISR and to BMS plus DEB in small vessel disease.
Aims: To present the immediate and short term outcome of our
experience with DEB.
Methods: We collected the data of all consecutive patients who
have undergone DEB at our centre in the last nine months. We
present their demographic profile, indications, procedural out-
comes and short term clinical outcomes.
Results: Nine patients (6 male & 3 female) underwent percuta-
neous interventionwith DEB at our centre in the last ninemonths.
Seven of them were for small vessel disease with a mean refer-
ence vessel diameter of 1.93±2.8 mm, and in two patient it was for
drug eluting stent ISR. Pre dilatation was done for all lesions
before DEB and cutting balloon was used for opening the ISR
before DEB. In all the seven patients with small vessel disease,
2mm balloons were used to dilate at or below the nominal pres-
sure and there good distal flow in all of them. Four of them were
paclitaxel eluting and four were sirolimus eluting balloons. As all
patients received a DES in another vessel they were all maintained
on oral dual anti-platelet therapy till the last follow up. The mean
follow up period was 148±63 days till which time there was no
major adverse cardiovascular events.
Conclusion: Drug eluting balloon in our experience has excellent
procedural and short term outcome for small vessel PCI and ISR.
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Background: Clopidogrel is metabolized in liver to its active form
by cytochrome P450 enzyme. The production of this enzyme is
controlled by several genes including CYP2C19 gene. Two single
nucleotide polymorphisms (SNPS) in the CYP2C12 gene have
found to be significantly associated with clopidogrel metabolism.
Methods: We studied 100 consecutive patients undergoing PCI for
acute coronary syndrome for single nucleotide polymorphism in
CYP2C19 gene, by GAAP e X METHOD.
Results: Out of 100 patients, 22 patients (22%) were poor metab-
oliser, and 34 patients (34%) were intermediate metaboliser, and
44% were normal metaboliser. Nearly 22% of patients who are
poor metaboliser were given newer agents like ticagrelor or pra-
sugrel and in intermediate metabolisers, the dose of clopidogrel
was increased to 150 mg OD.
Conclusion: CYP2C19 gene polymorphism is common in south
Indian population and poor metabolisers are given newer agents
to prevent stent thrombosis and recurrent cardiac events.
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Objective: The purpose of this study was to examine the safety
and efficacy of the Frontrunner XP CTO (chronic total occlusion)
catheter (Cordis Corporation) for recanalization of CTO of femo-
ropopliteal arteries.
Methods: A retrospective analysis of consecutive patients with
critical limb ischemia (CLI) who underwent femoropopliteal an-
gioplasty for TransAtlantic Inter-Society Consensus (TASC) class
D lesions between 2009 and 2011 was performed. Twenty-two
patients were enrolled with a mean age of 58.9 ± 11.5 years. Pa-
tients were enrolled with totally occluded arteries (mean occlu-
sion length, 18.0 ± 10.1 cm) that were treated with the Frontrunner
XP CTO catheter. All lesions were complex (TASC D) and 86.4% of
the lesions weremildly calcified. A Frontrunner catheter was used
to treat 22 CTOs after guidewire failure.
Results: Twenty-two of the 33 cases (66.7%) had failed previous
attempts of percutaneous intervention with conventional guide-
wire. The Frontrunner catheter was used to treat 22 CTOs after
guidewire failure. The Frontrunner catheter successfully facili-
tated the placement of a guidewire into the distal true lumen in 21
cases (95.5%). Thrombolysis in Myocardial Infarction 3 flow was
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